ArticleAging2026
Blue period - features of senescence 30 years after beta-galactosidase.
Article in Aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cellular senescence is a multi-phenotypic stress or damage response characterized by a stable cell cycle arrest and the secretion of a myriad of biologically active molecules, commonly known as the senescence-associated secretory phenotype (SASP). Thirty years ago, the identification of activated beta-galactosidase during senescence led to one of the first characterizations of senescent cell accumulation during biological aging. Since then, interventions that either selectively eliminate senescent cells or suppress the SASP have demonstrated that they are a major etiological agent for several degenerative pathologies associated with aging. As interest in the development of targeted therapeutics for senescence has grown, so too has the interest in the study of these cells. This has resulted in discovery of new features and phenotypes that often associate with senescence. Here, we review several of these key features of senescence, highlighting the strengths and caveats associated with each.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.